|
Brendan O’Leary, Ph.D. is an integral member of the Prism VentureWorks life sciences team, where he focuses on companies in the medical device, pharmaceutical and diagnostic sectors. Dr. O’Leary currently sits on the board of several life sciences companies including Locus Pharmaceuticals, Proteon Therapeutics, ROX Medical, and Trius Therapeutix. He was previously a director at BioRexis Pharmaceuticals (acquired by Pfizer). Prior to joining Prism Dr. O’Leary held senior operating positions at several biotechnology and medical technology companies including Meso Scale Discovery, a high throughput discovery start-up, and IGEN International, a leading medical diagnostics company that was acquired by Roche. Dr. O’Leary received his Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology and holds a B.A. in Chemistry and Economics from Middlebury College. | 